Singles Vaccine Linked with Lower Inflammation and Slower Biological Aging in Older Adults

Among U.S. adults aged 70 and older, receipt of a shingles vaccine (e.g., the recombinant zoster vaccine) was reported to be associated with biomarker patterns described as lower chronic inflammation and slower biological aging compared with peers who were not vaccinated.

The report framed these findings as differences observed between vaccinated and unvaccinated participants, rather than as evidence of causation. The observations were presented as coming from a cohort-based analysis of older adults with biomarker measurement.

Analyses were conducted within the U.S. Health and Retirement Study, focusing on more than 3,800 participants who were age 70 or older in 2016. Investigators compared biomarker-based indicators between those who had received the shingles vaccine and those who had not, and they reported that analyses accounted for demographic characteristics and health status differences between groups. Measures were described broadly as including inflammatory biomarkers and biologic aging readouts derived from epigenetic and transcriptomic data, alongside an overall biological aging score. The comparison remained anchored to vaccinated versus unvaccinated older adults at the time of biomarker assessment.

After accounting for reported between-group differences, vaccinated participants were described as having lower levels of inflammatory markers and slower epigenetic and transcriptomic aging than unvaccinated peers, alongside more favorable overall biological aging scores. These were characterized as convergent signals across biomarker and gene-based measures rather than as a single isolated result. No causal pathway was established in the report, and the findings were presented as associations observed in this older adult cohort.

The article also reported a time-since-vaccination analysis, noting that participants vaccinated four or more years before providing a blood sample were still described as showing slower epigenetic, transcriptomic, and overall biological aging compared with unvaccinated individuals. In that presentation, the persistence of differences was framed as an observed association over a multiyear interval rather than as a demonstrated durable effect. The authors were quoted as calling for replication and extension of these findings using longitudinal and experimental study designs, as reported in the news piece.

Overall, the report emphasized that additional study designs would be needed to evaluate these associations over time and under conditions better suited to testing causality.

Key Takeaways:

• In this cohort analysis of adults aged 70+, vaccinated participants were reported to have lower inflammation markers on average than unvaccinated participants.
• Vaccinated participants were described as having slower epigenetic and transcriptomic aging and more favorable composite biological aging scores than unvaccinated peers, after accounting for differences.
• Participants vaccinated ≥4 years before sampling were still reported to show slower biologic aging measures, and the authors called for longitudinal and experimental replication.